Lung Cancer 1.Tilelizumab’s second-line or third-line treatment of non-small cell lung cancer Phase III RATIONALE 303 trial reached its primary clinical endpoint. On November 17, BeiGene announced the interim analysis […]
1.Cell Rep: Uncovering the new molecular mechanism of tumor suppressor p53-induced cancer cell death doi: 10.1016 / j.celrep.2020.03.011 There has been an ongoing battle between cancer cells and p53. P53 is […]